Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Aljosja Rogiers Clear advanced filters

  • Turajlic and colleagues assess longitudinal antibody and cellular immune responses against SARS-CoV-2 variants of concern in patients with cancer, following either recovery from SARS-CoV-2 infection or vaccination, in two back-to-back reports from the CAPTURE study.

    • Annika Fendler
    • Scott T. C. Shepherd
    • Samra Turajlic
    ResearchOpen Access
    Nature Cancer
    Volume: 2, P: 1305-1320

  • There is increasing evidence that epigenetic mechanisms contribute to therapeutic resistance in cancer. Here the authors study AML patient samples and a mouse model of non-genetic resistance and find that transcriptional plasticity drives stable epigenetic resistance, and identify regulators of enhancer function as important modulators of resistance.

    • Charles C. Bell
    • Katie A. Fennell
    • Mark A. Dawson
    ResearchOpen Access
    Nature Communications
    Volume: 10, P: 1-15

  • Resistance to BRAF inhibitors limits their clinical benefit in melanoma patients. Here, the authors show that the Aryl hydrocarbon Receptor (AhR) is a key mediator of resistant genes and use resveratrol, an AhR antagonist, to revert resistance in melanoma bearing mice.

    • Sébastien Corre
    • Nina Tardif
    • Marie-Dominique Galibert
    ResearchOpen Access
    Nature Communications
    Volume: 9, P: 1-13

  • Gilot et al. have found that TYRP1 mRNA, in addition to coding for TYRP1 protein, can promote melanoma by sequestering the tumour suppressor miR-16, thus de-repressing the mRNA transcription of miR-16 target RAB17, which is involved in melanoma cell proliferation.

    • David Gilot
    • Mélodie Migault
    • Marie-Dominique Galibert
    Research
    Nature Cell Biology
    Volume: 19, P: 1348-1357

  • A known oncogene, MITF, resides in a region of chromosome 3 that is amplified in melanomas and associated with poor prognosis; now, a long non-coding RNA gene, SAMMSON, is shown to also lie in this region, to also act as a melanoma-specific survival oncogene, and to be a promising therapeutic target for anti-melanoma therapy.

    • Eleonora Leucci
    • Roberto Vendramin
    • Jean-Christophe Marine
    Research
    Nature
    Volume: 531, P: 518-522